![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Chemoresistance in gliomas accounts for the major cause of tumor progress and recurrence during comprehensive treatment with alkylating agents including temozolomide (TMZ). The oncogenic role of Enhancer of zeste homolog 2 (EZH2) has been identified in many solid malignancies including gliomas, though the accurate effect of EZH2 on chemotherapy resistance of gliomas has been elusive.
Objective: To elucidate the role of EHZ2 on TMZ resistance of gliomas and the molecular mechanisms.
Methods: Immunohistochemistry (IHC) and Reverse transcription-quantitative (RT-q) PCR, and western blot assay were performed for expressional analysis. Cell Counting Kit-8 (CCK-8) assay was applied to determine the TMZ sensitivity. EZH2-silencing lentivirus was generated for mechanic study.
Results: EZH2 was overexpressed in gliomas both at the transcriptional and protein levels. EZH2 level in glioma cell lines was positively correlated with resistance to TMZ, represented by the 50% inhibition rate (IC50). Moreover, there was increased TMZ sensitivity in EZH2-inhibited glioma cells than in the control cells. Furthermore, we determined that PARP1 was a common molecule among the downregulated DNA repair proteins in both U251 and U87 glioma cell lines after EZH2 inhibition. Specifically, we observed a spontaneous increase of PARP1 expression with TMZ treatment and interestingly, the increase of PARP1 could be also reduced by EZH2 inhibition in the glioma cells. Finally, combined treatment with lentivirus-induced EZH2 inhibition and a PARP1 inhibitor dramatically enhanced TMZ cytotoxicity compared with either one alone.
Conclusion: EZH2-PARP-1 signaling axis is possibly responsible for the chemoresistance of gliomas to TMZ. Simultaneously inhibiting these two genes may improve the outcome of TMZ chemotherapy.
Keywords: EZH2, glioma, chemoresistance, temozolomide, DNA repair, PARP1.
[http://dx.doi.org/10.1038/s41582-019-0220-2] [PMID: 31227792]
[http://dx.doi.org/10.1093/neuonc/noab106] [PMID: 34185076]
[http://dx.doi.org/10.1056/NEJMoa043330] [PMID: 15758009]
[http://dx.doi.org/10.1016/j.tips.2017.05.002] [PMID: 28602395]
[http://dx.doi.org/10.1038/nature04431] [PMID: 16357870]
[http://dx.doi.org/10.1038/aps.2013.161] [PMID: 24362326]
[http://dx.doi.org/10.1186/s13045-020-00937-8] [PMID: 32723346]
[http://dx.doi.org/10.1038/nm.4036] [PMID: 26845405]
[http://dx.doi.org/10.1111/j.1365-2990.2010.01132.x] [PMID: 20946108]
[http://dx.doi.org/10.1016/j.jns.2013.09.030] [PMID: 24139839]
[http://dx.doi.org/10.3892/or.2012.2033] [PMID: 22992977]
[http://dx.doi.org/10.1016/j.ejphar.2021.174177] [PMID: 34015321]
[PMID: 31858557]
[http://dx.doi.org/10.1016/j.biopha.2021.112532] [PMID: 34906772]
[http://dx.doi.org/10.3892/ol.2021.12826] [PMID: 34113393]
[http://dx.doi.org/10.1111/j.1471-4159.2012.07781.x] [PMID: 22564186]
[http://dx.doi.org/10.1007/s11010-008-9722-8] [PMID: 18259841]
[http://dx.doi.org/10.1111/cas.13528] [PMID: 29427543]
[http://dx.doi.org/10.1158/0008-5472.CAN-16-1151] [PMID: 27793847]
[http://dx.doi.org/10.3892/or.2018.6322] [PMID: 29565460]
[http://dx.doi.org/10.1016/j.tibs.2010.02.009] [PMID: 20346678]
[http://dx.doi.org/10.3390/cancers14194761] [PMID: 36230683]
[http://dx.doi.org/10.7150/thno.48101] [PMID: 33408782]
[http://dx.doi.org/10.1038/s41598-021-84708-6] [PMID: 33712646]
[http://dx.doi.org/10.1016/j.brainresbull.2011.07.010] [PMID: 21807073]
[http://dx.doi.org/10.1159/000306139] [PMID: 20357518]
[PMID: 25400745]
[http://dx.doi.org/10.1016/j.dnarep.2018.08.022] [PMID: 30177435]
[http://dx.doi.org/10.7150/thno.41219] [PMID: 32194873]
![Wayfinder Image](/images/wayfinder.jpg)